Zentalis Pharmaceuticals (ZNTL) Change in Accured Expenses (2019 - 2026)

Zentalis Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$1.5 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 63.93% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$14.7 million (down 116.95% YoY), while the FY2025 annual figure was -$17.3 million, up 3.92% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.5 million, down from -$733000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $11.8 million in Q2 2024, with the low at -$15.2 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is -$1.4 million (2023), against an average of -$608411.8.
• Peak annual rise in Change in Accured Expenses reached 368.48% in 2024, while the deepest fall reached 980.72% in 2024.
• Zentalis Pharmaceuticals' Change in Accured Expenses stood at $5.0 million in 2022, then soared by 105.88% to $10.4 million in 2023, then plunged by 124.64% to -$2.6 million in 2024, then jumped by 71.39% to -$733000.0 in 2025, then tumbled by 97.95% to -$1.5 million in 2026.
• Business Quant data shows ZNTL's Change in Accured Expenses at -$1.5 million in Q1 2026, -$733000.0 in Q4 2025, and -$2.0 million in Q3 2025.